Current stock page

Financial Data

BBIO Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

BBIOBridgeBio Pharma, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$78.30+$0.13 (+0.17%)

Latest quote

  • Momentum
    69
  • Value
    55
  • Quality
    66
  • Risk resilience
    62
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$353.17M$243.68M$194.52M$154.18M$120.7M$110.57M$116.63M$5.88M
Gross Profit$332.72M$228.63M$184.09M$138.76M$114.14M$106.91M$113.99M$3.8M
Operating Income-$11.64M-$107.08M-$105.96M-$185.24M-$145.2M-$134.28M-$104.37M-$226.03M
Net Income-$56.71M-$152.22M-$164.04M-$197.24M-$182.74M-$181.9M-$167.42M-$265.05M
EPS-$0.42-$0.78-$0.84-$1-$0.96-$0.95-$0.88-$1.4
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$44.17M-$71.1M-$197.28M-$56.42M-$109.57M-$80.68M-$199.24M-$195.33M
Capital Expenditure-$290K-$443K-$69K-$4.53M-$470K-$5.09M-$1.6M-$3.24M
Free Cash Flow-$44.46M-$71.54M-$197.35M-$60.95M-$110.04M-$85.78M-$200.83M-$198.56M
Net Cash Provided By Operating Activities-$44.17M-$71.1M-$197.28M-$56.42M-$109.57M-$80.68M-$199.24M-$195.33M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$2.16B$1.22B$1.37B$936.03M$998.25M$1.08B$881.64M$919.34M
Total Debt$2.49B$2.49B$3.38B$2.73B$1.86B$2.68B$1.86B$1.73B
Cash And Cash Equivalents$1.53B$677.91M$879.89M$570.12M$642.95M$749.4M$540.6M$681.1M
Total Liabilities$3.82B$3.72B$3.64B$3.01B$2.92B$2.86B$2.52B$2.38B
Total Stockholders Equity-$1.66B-$2.52B-$2.27B-$2.08B-$1.93B-$1.79B-$1.65B-$1.47B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio11.85———————
P/S ratio16.23———————
Debt To Equity————————
Free Cash Flow Yield-3.80%-3.57%-3.46%-3.40%-4.69%-7.12%-7.36%-7.60%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio11.85———————
P/S ratio16.23———————
Return On Equity————————
Debt To Equity————————

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-25.76x
Pb-9.23x
Revenue Growth Yoy192.60%
EPS Growth Yoy56.25%
Gross Margin93.51%
Operating Margin-43.35%
ROE26.76%
ROIC-23.63%
Debt To Equity-1.5
FCF Yield-2.45%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$78.30
Volume1.15M
RSI (14)64.96
MACD2.65
MACD signal1.98
MACD histogram0.67
ADX (14)38.85
SMA (50)$69.98
SMA (200)$72.69
ATR (14)$2.70
Historical volatility (annualized)39.06%
Volume (20-day average)3.02M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score62/100
Beta0.95
Annual volatility44.14%
Max Drawdown-29.80%
Sharpe Ratio0.55
VaR (95%, 1-day)-3.96%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

BBIO Financial Data FAQ

What is BridgeBio Pharma, Inc.'s revenue?

BridgeBio Pharma, Inc.'s revenue is one of the core financial data points for BBIO. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is BridgeBio Pharma, Inc.'s revenue growing?

Revenue growth shows whether BridgeBio Pharma, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is BBIO's EPS?

BBIO's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is BridgeBio Pharma, Inc.'s net income?

BridgeBio Pharma, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does BridgeBio Pharma, Inc. generate?

Free cash flow shows how much cash BridgeBio Pharma, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does BridgeBio Pharma, Inc. have?

Cash and debt help frame BBIO's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.